Bambusa Therapeutics
PublicBambusa Therapeutics is now publicly traded
The data on this page reflects Bambusa Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series A
Extension
Nov 17, 2025
Est. Valuation at Exit
$555M
Total Funding Raised
$145M
Company Overview
Bambusa Therapeutics has raised $145M. It was founded in 2024.
Bambusa Therapeutics is a biotechnology company that develops bispecific antibodies for the treatment of immunological and inflammatory disorders.
AI Layer
Non-AI
Bambusa Therapeutics Comparables
Compare Bambusa Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Attovia Therapeutics | 80% | |
| Belenos Biosciences Inc. | 74% | |
| Prometheus Therapeutics Inc. | 73% |
For institutional investors. Book with your work email.
Bambusa Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 17, 2025 | ||||
| Series A | Feb 14, 2025 | ||||
| Seed | Sep 9, 2024 | ||||
| Series A Extension | Nov 17, 2023 |
For institutional investors. Book with your work email.
Bambusa Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series A, Series A Extension |
| Salvia | Series A, Series A Extension, Seed |
| Janus Henderson Group | Series A, Series A Extension |
| ADAR1 Capital Management | Series A, Series A Extension |
| RA Capital Management | Series A Extension, Series A |
| Kohlberg Kravis Roberts | Series A |
| 渶策资本 | Series A, Series A Extension, Seed |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingOct 30, 2026
Bambusa Therapeutics, Inc., a dermatology and autoimmune disease biotech, receives $169M in an upsized US IPO to support research in Massachusetts on Oct 30th '26.
- has_valuationOct 30, 2026
Bambusa Therapeutics, Inc. has a roughly $816M market capitalization at IPO pricing on Oct 29th '26.
- goes_publicOct 9, 2026
Bambusa Therapeutics, Inc. files for an initial public offering to fund trials of drugs for eczema and other inflammation disorders in Massachusetts on Oct 9th '26.
- is_developingOct 7, 2026
Bambusa Therapeutics, Inc. is developing BBT001, a half-life-extended bispecific antibody targeting IL-4Rα and interleukin-31, for atopic dermatitis and chronic spontaneous urticaria.
- hiresOct 7, 2026
Bambusa Therapeutics, Inc. names Jonathan I. Lieber chief financial officer as it advances its bispecific antibody pipeline for immunology and inflammation diseases.
For institutional investors. Book with your work email.
Bambusa Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.